Analysts have been eager to weigh in on the Healthcare sector with new ratings on Deciphera Pharmaceuticals (DCPH – Research Report), Atara Biotherapeutics (ATRA – Research Report) and Nkarta (NKTX – Research Report).
Deciphera Pharmaceuticals (DCPH)
In a report issued on May 14, Bradley Canino from Stifel Nicolaus downgraded Deciphera Pharmaceuticals to Hold, with a price target of $26.00. The company’s shares closed last Wednesday at $25.45, close to its 52-week high of $25.55.
According to TipRanks.com, Canino is a 3-star analyst with an average return of
Deciphera Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $24.55, a -3.6% downside from current levels. In a report issued on April 30, Barclays also upgraded the stock to Hold with a $26.00 price target.
See the top stocks recommended by analysts >>
Atara Biotherapeutics (ATRA)
Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics on May 14 and set a price target of $2.20. The company’s shares closed last Wednesday at $0.64.
According to TipRanks.com, Burnett ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Atara Biotherapeutics with a $4.18 average price target.
Nkarta (NKTX)
In a report issued on May 14, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Nkarta, with a price target of $18.00. The company’s shares closed last Wednesday at $6.88.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
Nkarta has an analyst consensus of Strong Buy, with a price target consensus of $18.80, implying a 178.1% upside from current levels. In a report issued on May 9, Canaccord Genuity also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DCPH:
